<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991910</url>
  </required_header>
  <id_info>
    <org_study_id>RCTRHDMS</org_study_id>
    <nct_id>NCT03991910</nct_id>
  </id_info>
  <brief_title>The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients</brief_title>
  <official_title>The Effect of Ramipril in Suppressing Gene Expression of Fibrosis in Cardiac Mitral Stenosis in Patients With Rheumatic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective propose: to investigate the effect of Ramipril in suppressing gene expression of
      ST2 in the cardiac mitral valve in patients with Rheumatic Heart Disease. It is hypothesized
      that the effect of Ramipril suppressing gene expression of ST2 in the cardiac mitral valve in
      patients with Rheumatic Heart Disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy of secondary prevention is limited in the prevention of RHD progression. For this
      reason, new strategies and therapies are needed to prevent the progression of RHD.
      Neutralizing inflammatory cytokines or antagonizing their receptor function has been
      considered as a useful therapeutic strategy to treat autoimmune diseases. In this respect,
      new therapies targeting ST 2 and their receptors as studied in some autoimmune diseases may
      promise a new approach for patients with RHD. ACE inhibitor were agents with anti-fibrosis
      effects. The investigators keen to investigate the effect of Ramipril in suppressing gene
      expression of fibrosis in cardiac mitral valve of patients with Rheumatic Heart Disease in
      the National Cardiac Center Harapan Kita hospital Jakarta Indonesia. This study was designed
      as an experimental study. Patients with mitral stenosis valvular dysfunction due to rheumatic
      process planned for cardiac valve replacement operation were given Ramipril or placebo for a
      minimum 4 weeks (1 month) and maximum of 12 weeks (3 months) before the surgery. ST2 was
      check for fibrosis marker. This study will be conducted in the Department of Cardiology and
      Vascular Medicine, University Indonesia, National Cardiac Center Harapan Kita Hospital,
      Jakarta, Indonesia from June 2019 - August 2021.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">August 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>pre post test design with placebo control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>study participants do not know whether they become treatment group or control group the investigator does not know which participant in each group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ST2 plasma level</measure>
    <time_frame>a year</time_frame>
    <description>plasma level of ST2 measured by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ST2 expression in mitral valve tissue</measure>
    <time_frame>a year</time_frame>
    <description>expression of ST2 in mitral valve tissue, using immunohistochemistry method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP concentration (pg/ml)</measure>
    <time_frame>a year</time_frame>
    <description>concentration of NT-proBNP, plasma markers for cardiac dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global strain</measure>
    <time_frame>a year</time_frame>
    <description>echocardiography parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ejection fraction</measure>
    <time_frame>a year</time_frame>
    <description>echocardiography parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>a year</time_frame>
    <description>related symptoms will be graded in class I to IV according to NYHA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Rheumatic Heart Disease</condition>
  <condition>Mitral Stenosis</condition>
  <condition>Rheumatic Mitral Stenosis</condition>
  <condition>Fibrosis; Heart</condition>
  <condition>ACE Inhibitor</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control patients will be given a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramipril 5 mg treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking)</description>
    <arm_group_label>control</arm_group_label>
    <other_name>control group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril 5Mg Oral Capsule</intervention_name>
    <description>the treatment group will be given Ramipril 5 mg inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking)</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>treatment group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mitral valve stenosis or a combination

          -  aged more than 18 years

          -  undergo cardiac valve replacement operation with or without a tricuspid valve repair,

          -  patients with systolic blood pressure (SBP) ≥ 100 mmHg and diastolic blood pressure
             (DBP) ≥ 60 mmHg

          -  passed in medication phase without side effect minimum 4 weeks until operation
             schedule

        Exclusion Criteria:

          1. Patients with congenital heart disease

          2. patients with non-mitral valve surgery

          3. patients with coronary artery bypass surgery

          4. patients who refuse to join this study.

          5. adults aged over 65 years or older

          6. pregnant women

          7. patients with autoimmune disease.

          8. Patients with persistent hypotension (systolic blood pressure (BP) &lt; 100 mm Hg)

          9. severe aortic stenosis (aortic valve orifice &lt; 0.75 cm2 )

         10. chronic renal dysfunction with serum creatinine &gt; 2.5 mg/ dL,

         11. known ACEI intolerance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ade Meidian Ambari, MD,FIHA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitas Indonesia, RSPJN harapan kita</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ade Meidian Ambari, MD, FIHA</last_name>
    <phone>021-5684085</phone>
    <phone_ext>2209</phone_ext>
    <email>dr_ade_meidian@yahoo.co.id</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ade Meidian Ambari</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>1140</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ade Meidian Ambari, MD,FIHA</last_name>
      <phone>021-5684085</phone>
      <phone_ext>2209</phone_ext>
      <email>dr_ade_meidian@yahoo.co.id</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, Iacoviello M, Scicchitano P. A novel cardiac bio-marker: ST2: a review. Molecules. 2013 Dec 11;18(12):15314-28. doi: 10.3390/molecules181215314. Review.</citation>
    <PMID>24335613</PMID>
  </reference>
  <results_reference>
    <citation>Wei Q, Liu H, Liu M, Yang C, Yang J, Liu Z, Yang P. Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure. Sci Rep. 2016 Sep 19;6:33677. doi: 10.1038/srep33677.</citation>
    <PMID>27642098</PMID>
  </results_reference>
  <results_reference>
    <citation>Shi Q, Abusarah J, Baroudi G, Fernandes JC, Fahmi H, Benderdour M. Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis. Arthritis Res Ther. 2012 Oct 18;14(5):R223. doi: 10.1186/ar4062.</citation>
    <PMID>23079082</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Ade Meidian Ambari</investigator_full_name>
    <investigator_title>MD, cardiologist, head of cardiovascular prevention and rehabilitation</investigator_title>
  </responsible_party>
  <keyword>Rheumatic Heart Disease</keyword>
  <keyword>Mitral Stenosis</keyword>
  <keyword>Rheumatic Mitral Stenosis</keyword>
  <keyword>Valve Fibrosis</keyword>
  <keyword>ramipril</keyword>
  <keyword>ST2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Heart Disease</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Mitral Valve Stenosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

